2 cheap stocks I think Warren Buffett would love

As a long-term investor, I could do a lot worse than listen to a stock-investing genius like Warren Buffett. Here are two top stocks I think he’d approve of.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Warren Buffett is one of the most successful, and by extension most famous, value-loving investors in the business. Picking low-cost stocks with his Berkshire Hathaway firm and watching them balloon in value has made the ‘Sage of Omaha’ worth an estimated $100.4bn today.

But Buffett’s investing strategy is about much more than just identifying undervalued stocks. Here are two cheap UK shares I think would whet the billionaire investor’s appetite for other reasons.

The FTSE 100 pharma giant

Buying companies which have clear and effective ‘economic moats’ is a cornerstone of Buffett’s money-making strategy. This is the name given to any long-term advantage a business has over the competition. They can include anything from market-leading products and a lower cost base versus rival operators, to creating high switching costs for customers looking to take their custom elsewhere.

GlaxoSmithKline (LSE: GSK) has one of the most formidable economic moats out there, namely significant patent protection. This stops rival drugs manufacturers moving in and copying its expensively-assembled portfolio of world-class treatments. According to DrugPatentWatch, the FTSE 100 company has 1,048 product patents in effect spanning 59 countries.

Pharmaceuticals development is a notoriously difficult business. And GlaxoSmithKline’s great track record of producing market-leading patented products is no guarantee of future success. But I’d argue that this UK share’s undemanding forward price-to-earnings (P/E) ratio of around 13 times still offers terrific value. Especially considering its strong position in many fast-growing therapy areas like oncology, vaccines and respiratory disorders, and the enormous financial clout it has to plough into R&D.

I think Buffett, who already owns Merck and Bristol Myers Squibb, would love this UK share.

Another stock Warren Buffett might adore

The popularity of Britvic’s (LSE: BVIC) brands seems to be timeless. The likes of Pepsi, Robinsons, Lipton and R Whites have been keeping consumers refreshed for many decades (some even have their roots in the 1800s). And their popularity is a strong as ever.

Buffett loves firms with robust brand power, as shown by Berkshire Hathaway’s holdings in Apple, Kraft Heinz and Coca-Cola. This economic moat helps demand for their products grow stronger than the broader market when consumer spending comes under pressure. It also allows companies like Britvic to raise prices without having to worry too much about how this will affect sales volumes.

I think Britvic’s a top buy despite the threat posed by a growing carbon dioxide shortage, a critical component in the company’s fizzy drinks. European fertilizer plants are shutting down operations in response to soaring energy prices, including two major facilities here in the UK. This could naturally damage beverages production and jack up costs considerably.

City analysts currently think Britvic’s earnings will jump 24% in the upcoming financial year (to September 2022). This leaves it trading on a bargain-basement forward price-to-earnings growth (PEG) ratio of 0.7. In my opinion, this provides the sort of bang for your buck that value investors like Warren Buffett adore.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Apple and Bristol Myers Squibb. The Motley Fool UK has recommended Britvic and GlaxoSmithKline and has recommended the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Persimmon’s share price surges 7% on double boost! Can it keep rising?

Persimmon's share price is surging, up 11% at one point earlier on Tuesday. Could this be the start of a…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

What on earth’s happening to the Greggs share price?

Harvey Jones says Greggs’ share price has shown surprising resilience in the recent stock market turmoil, but the FTSE 250…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Barclays shares are down 18%. Time to consider buying?

Barclays’ shares have plummeted in recent weeks. Edward Sheldon looks at what’s going on and provides his view on the…

Read more »

Hand flipping wooden cubes for change wording" Panic" to " Calm".
Investing Articles

Ready for a stock market crash? Here’s what Warren Buffett says to do

There are several reasons to think a stock market crash might not be far off. But it’s times like these…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How many Barclays shares do I need to buy for a £1,000 passive income?

Dividends from Barclays shares are about to skyrocket as management outlines plans to return £15bn to shareholders. Is this a…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

This fallen FTSE 100 darling could be one of the best shares to buy in March

There was a time when investors couldn’t get enough of this FTSE 100 stock. Now I reckon it might be…

Read more »

Investing Articles

Around £16 now, here’s why Greggs shares ‘should’ be trading just over £25

Greggs shares are trading at a serious discount to where they ‘should’ be, based on record sales, iconic branding and…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

This FTSE 250 turnaround story is now delivering a standout 7.3% dividend yield!

This FTSE 250 income play has held its payout steady for years and is now showing early signs of renewed…

Read more »